Lung Cancer

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

THIO plus cemiplimab generated a potential survival benefit in pretreated advanced non–small cell lung cancer.

The EMA’s CHMP has issued a positive opinion supporting the approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

The CHMP has recommended approval for durvalumab in limited-stage small cell lung cancer following platinum-based chemoradiation.

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

The REZILIENT1 study of zipalertinib in pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations met its primary end point of ORR.

Findings from an oncogene overlap study in NSCLC support the potential clinical impact of high-level amplification of MET, HER2, and KRAS defined by NGS.

Alexander Watson, MD, DPhil, FRCPC, explains how the relationship between driver positivity and amplification status affects same-gene alteration enrichment.

Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.

Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.

This segment discusses the importance of biomarker testing in lung cancer, challenges in implementation such as tissue adequacy and result delays, and strategies to enhance testing in both academic and community settings through local champions and education.

This segment explores the role of biomarker testing in optimizing outcomes for non-small cell lung cancer (NSCLC), highlighting challenges in early-stage testing, the importance of multidisciplinary collaboration, and recent advances like the LAURA trial that emphasize the need for comprehensive biomarker assessment.

This video segment discusses defining resectability for Stage III lung cancer, the importance of a multidisciplinary approach to decision-making involving surgical, medical, radiation oncology, and diagnostic teams, and the role of patient engagement in tailoring treatment plans to individual priorities, risks, and physiological suitability.

The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.